51 – 60 of 120
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Healthcare professionals' perceptions of working on lifestyle management for patients with early rheumatoid arthritis - a qualitative study
(2023) In International Journal of Qualitative Studies on Health and Well-being 18(1). p.2241225-2241225
- Contribution to journal › Article
-
Mark
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis : 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
- Contribution to journal › Article
-
Mark
Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis
- Contribution to journal › Article
-
Mark
The effect of a tight control regime with monthly follow-up on remission rates and reported pain in early rheumatoid arthritis
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Contribution to journal › Scientific review
-
Mark
Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout
- Contribution to journal › Article
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
- Contribution to journal › Article
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
- Contribution to journal › Article
-
Mark
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
- Contribution to journal › Article
